International Prognostic Score for Asymptomatic Early-stage CLL (IPS-E)

The IPS‑E predicts the likelihood of requiring first treatment in asymptomatic early‑stage CLL using IGHV status, lymphocyte count, and palpable lymphadenopathy 1.

Unmutated IGHV genes
No0Yes+1
Absolute lymphocyte count > 15×10^9/L
No0Yes+1
Palpable lymph nodes
No0Yes+1

Indicações de Uso

Used in asymptomatic early‑stage CLL (Rai 0–I or Binet A) to estimate risk of needing first treatment based on 3 factors (unmutated IGHV, ALC >15×10⁹/L, palpable nodes). Derived and validated in 4933 patients with clear 5‑year TTFT separation: 8% vs 28% vs 61% for low/intermediate/high risk 1 [Level I evidence]. Guides follow‑up intensity, patient counseling, and selection for early‑intervention clinical trials.

Insights e Precauções

Identifies three adverse factors—unmutated IGHV, ALC >15×10⁹/L, palpable nodes—each adding one point and stratifying patients into groups with markedly different 5‑year treatment risks (8%, 28%, 61%) 1 [Level I evidence].
Use only to estimate time to first treatment in asymptomatic early-stage CLL; it does not guide therapy, omits cytogenetics/TP53 status, and may underestimate risk in biologically high‑risk disease.